Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5454
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning ; day:1 ; month:7 ; year:2022 ; pages:1-6
Eye ; (1.7.2022), 1-6
- Urheber
-
Holomcik, David
Seeböck, Philipp
Gerendas, Bianca S.
Mylonas, Georgios
Najeeb, Bilal Haj
Schmidt-Erfurth, Ursula
Deak, Gabor
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-022-02156-6
- URN
-
urn:nbn:de:101:1-2022082119025920313453
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Holomcik, David
- Seeböck, Philipp
- Gerendas, Bianca S.
- Mylonas, Georgios
- Najeeb, Bilal Haj
- Schmidt-Erfurth, Ursula
- Deak, Gabor
- SpringerLink (Online service)
Ähnliche Objekte (12)
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)